Notably, we showed that patients with tumors having higher TNF-α and TWEAK tumor secretion capacity in vitro also had correspondingly elevated levels of these cytokines in their perilymph, suggesting that our in vitro system could predict in vivo levels of these hearing loss-associated biomarkers. Here, TNF is linked to neoplasm.